Melatonin ameliorates experimental hepatic fibrosis induced by carbon tetrachloride in rats

doi:10.3748/wjg.15.1452

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 12

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3973)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

394

HTML

3136

Figures (1-2)

208

Tables (1-4)

235

Sum=3973

Mar 28, 2009 (publication date) through Nov 8, 2024

Times Cited of This Article

Times Cited (47)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Original Articles

World J Gastroenterol. Mar 28, 2009; 15(12): 1452-1458
Published online Mar 28, 2009. doi: 10.3748/wjg.15.1452

Table 1 Pathologic grading of hepatic fibrosis in different groups

Group	Dose (mg/kg)	n	Pathologic grading of hepatic fibrosis					u value
	Dose (mg/kg)		0	I	II	III	IV
Normal	-	11	11	0	0	0	0	5.5681^b
Model	-	13	0	0	1	6	6	-
NAC	100	12	0	2	5	3	2	1.8838
MEL	2.5	11	0	2	4	2	3	1.5568
	5	13	0	2	4	3	4	1.3662
	10	12	0	4	4	1	3	2.1720^a

u represents the Ridit value of the two groups, P < 0.05 indicates u > 1.96; P < 0.01 indicates u > 2.58;

^aP < 0.05,

^bP < 0.01 vs model group.

Table 2 Effect of melatonin on serum ALT, AST levels and A/G value in different groups (mean ± SD)

Group	Dose (mg/kg)	n	ALT (U/L)	AST (U/L)	A/G
Normal	-	11	70.00 ± 35.27	139.82 ± 72.83	0.94 ± 0.40
Model	-	13	286.23 ± 121.91^b	431.00 ± 166.35^b	0.74 ± 0.09
NAC	100	12	194.42 ± 90.83^b^c	293.33 ± 94.60^b^c	0.78 ± 0.11
MEL	2.5	11	211.09 ± 97.03^b	357.09 ± 153.26^b	0.68 ± 0.15
	5	13	201.15 ± 101.16^b^c	321.23 ± 162.48^b^c	0.77 ± 0.15
	10	12	178.67 ± 103.14^b^d	292.42 ± 126.23^b^c	0.73 ± 0.07

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; A: Albumin; G: Globumin.

^bP < 0.01 vs normal control group;

^cP < 0.05 vs model control group;

^dP < 0.01 vs model control group.

Table 3 MDA content and GPx activity in liver homogenates of different groups (mean ± SD)

Group	Dose (mg/kg)	n	MDA (noml/mg prot)	GPx (U/mg prot)
Normal	-	11	4.3 ± 1.87	80.68 ± 10.76
Model	-	13	7.89 ± 1.49^b	49.13 ± 8.72^b
NAC	100	12	6.29 ± 1.36^b^c	64.68 ± 8.22^b^d
MEL	2.5	11	6.84 ± 1.10^b	53.44 ± 9.35^b
	5	13	6.29 ± 1.42^b^c	57.38 ± 7.65^b^c
	10	12	6.25 ± 2.27^b^c	61.39 ± 13.15^b^d

MDA: Malondialdehyde; GPx: Glutathione peroxidase.

^bP < 0.01 vs normal control group;

^cP < 0.05 vs model control group;

^dP < 0.01 vs model control group.

Table 4 Serum HA, LN and PIIINP levels in different groups (mean ± SD)

Group	Dose (mg/kg)	n	HA (&mgr;g/L)	LN (&mgr;g/L)	PIIINP (&mgr;g/L)
Normal	-	11	71.65 ± 27.64	37.65 ± 6.09	26.41 ± 7.28
Model	-	13	201.10 ± 68.46^b	55.26 ± 12.30^b	35.88 ± 5.92^b
NAC	100	12	131.31 ± 58.58^a^c	48.28 ± 4.93^b	32.89 ± 3.90^b
MEL	2.5	11	174.41 ± 72.99^b	48.15 ± 6.40^b	34.21 ± 5.76^b
	5	13	153.54 ± 86.19^b	48.22 ± 9.51^b	33.12 ± 4.71^b
	10	12	135.71 ± 76.03^a^c	45.89 ± 11.71^a^c	31.99 ± 6.09^a

HA: Hyaluronic acid; LN: Laminin; PIIINP: Procollagen III N-terminal peptide.

^aP < 0.05 vs normal control group;

^bP < 0.01 vs normal control group;

^cP < 0.05 vs model control group.

Citation: Hong RT, Xu JM, Mei Q. Melatonin ameliorates experimental hepatic fibrosis induced by carbon tetrachloride in rats. World J Gastroenterol 2009; 15(12): 1452-1458
URL: https://www.wjgnet.com/1007-9327/full/v15/i12/1452.htm
DOI: https://dx.doi.org/10.3748/wjg.15.1452